“…The fact is that, whilst specificity remains high (according to our findings in the cognitive part of our research), there is significant a return of some depressive symptoms, meaning that we might question whether the mechanism is directly memory specificity, but some other generalised benefit or pleasure of using the device, for example. As the advanced IADLs are known to be the first to be affected by the preclinical and mild stages of AD (Sikkes et al, 2011), and, as such, are those that need early neuropsychological interventions (Clare, Wilson, Carter, Hodges and Adams 2001;Clare et al, 2010), this short term effect of both SenseCam and Memo+ for advanced IADLs is of value for early intervention in AD (Silva et al, 2016). However, for future study, as we only accounted for perceived functional capacity, these findings should be correlated with more objective measures of functionality (direct observation, etc.)…”